Generic Name and Formulations:
Thiothixene 1mg, 2mg, 5mg, 10mg; caps.
Indications for Thiothixene:
Individualize. Mild: initially 2mg three times daily, may subsequently increase to 15mg/day. Severe: initially 5mg twice daily. Usual optimal dose: 20–30mg daily; if needed, may increase to max 60mg/day.
Circulatory collapse. Coma. CNS depression. Blood dyscrasias.
Increased mortality in elderly patients with dementia-related psychosis.
Elderly with dementia-related psychosis (not approved use): increased risk of death. History of convulsive disorders or alcohol withdrawal. Exposure to extreme heat. Cardiovascular disease. Pre-existing low WBC or history of drug induced leukopenia/neutropenia; monitor CBCs during 1st few months of treatment. If significant neutropenia occurs; monitor for fever and signs of infections; discontinue if ANC<1000/mm3. Hepatic impairment. Neonates: risk of extrapyramidal and/or withdrawal symptoms post delivery (due to exposure during 3rd-trimester pregnancy). Pregnancy.
Additive effects with hypotensive agents, CNS depressants and alcohol. Potentiates barbiturates. Antagonized by carbamazepine. Caution with concomitant atropine or related drugs.
Tardive dyskinesia, hypotension, drowsiness, insomnia, jaundice, blood dyscrasias, may mask emetic signs of overdosage or disease, lowered seizure threshold, rash, photosensitivity, hyperprolactinemia, anticholinergic effects, pigmentary retinopathy, lenticular pigmentation, extrapyramidal reactions, neuroleptic malignant syndrome (monitor).
Neurology Advisor Articles
- Case Study Report: Herbal Supplement Kratom Associated With Neonatal Abstinence Syndrome
- Seizure Monitoring Smartwatch Cleared for Use in Children
- Ocrelizumab Reduces Upper Extremity Disability Progression Risk in PPMS
- Steps to Facilitate Rapid Reperfusion to Improve Poststroke Outcomes
- Cerebellar Stimulation May Help Improve Gait and Balance Recovery in Stroke
- Very Early Mobilization After Stroke Does Not Improve Survival Over Usual Care
- Alemtuzumab Linked to Clinical and MRI Disease Remission in Multiple Sclerosis
- Cognitive Decline Worsens With Memantine, ChEIs in Patients With Alzheimer's
- Cervical Dysfunction Needs Clarification to Identify Link With Headache
- Levodopa Inhalation Powder Approved for Parkinson Disease
- Risk for Conversion of MS Varies With Different Therapies
- Breakdown of Blood-Brain Barrier May Drive Dementia
- FDA: Food Inspections to Resume Despite Ongoing Funding Lapse
- First Generic Version of Sabril Tablets Gets FDA Approval
- Supine Positioning After Greater Occipital Nerve Block May Improve Outcomes